CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $19.25B, above the global median of $1.18B
- FinancialsAltman Z-Score 2.46: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.95%Above 5Y avg (0.85%)
Annual Rate
USD 0.96Paid quarterly
Payout Ratio
23.3%Sustainable
Paying Dividends
15 yr
Payback Period
99.3 yr
Last Ex-Dividend
Jun 25, 2026
Last Payment
Jul 31, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
19.25BUSDvs all stocks (USD)
Trailing P/E
24.33xRevenue (TTM)
8.51BUSDvs all stocks (USD)
Profit Margin
9.48%Beta
0.4620xvs all stocks
52-Week Change
-4.89%vs all stocks
Forward Annual Dividend Yield
0.95%vs all stocks
Market Capitalization
19.25BUSDvs all stocks (USD)
Enterprise Value
26.12BUSDvs all stocks (USD)
Trailing P/E
24.33xForward P/E
11.05xPEG Ratio
0.7204xPrice to Sales (TTM)
2.25xPrice to Book (MRQ)
1.51xEnterprise to Revenue
3.07xEnterprise to EBITDA
10.22xGross Margin
70.81%Profit Margin
9.48%Operating Margin
17.96%Return on Assets (TTM)
3.96%Return on Equity (TTM)
6.41%Revenue (TTM)
8.51BUSDvs all stocks (USD)
Revenue per Share (TTM)
43.50USDUpdated Aug 29, 2026Quarterly Revenue Growth
4.80%Gross Profit (TTM)
5.95BUSDvs all stocks (USD)
EBITDA (TTM)
2.52BUSDvs all stocks (USD)
Net Income (TTM)
806.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
29.80%Operating Cash Flow (TTM)
1.74BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
1.09BUSDvs all stocks (USD)
Forward Annual Dividend Rate
0.9600USDUpdated Aug 29, 2026Forward Annual Dividend Yield
0.95%vs all stocks
Trailing Annual Dividend Rate
0.9600USDUpdated Aug 29, 2026Trailing Annual Dividend Yield
0.95%vs all stocks
5-Year Average Dividend Yield
0.85%vs all stocks
Payout Ratio
23.30%Minority Interest (Equity)
8.10MUSDFY2025 · Dec 31, 2025Revenue
8.23BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
2.49BUSDFY2025 · Dec 31, 2025Gross Profit
5.74BUSDFY2025 · Dec 31, 2025Operating Income
1.36BUSDvs all stocks (USD)
Pre-tax Income
830.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
125.70MUSDFY2025 · Dec 31, 2025Net Income
705.10MUSDFY2025 · Dec 31, 2025EBIT
1.12BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.48BUSDFY2025 · Dec 31, 2025Research & Development
458.50MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
3.26BUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
292.80MUSDFY2025 · Dec 31, 2025EPS (Basic)
3.56USDFY2025 · Dec 31, 2025EPS (Diluted)
3.55USDFY2025 · Dec 31, 2025Basic Shares Outstanding
198.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
198.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
705.10MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
100.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
1.60BUSDFY2025 · Dec 31, 2025Free Cash Flow
1.37BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
591.90MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
705.10MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.09BUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-87.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
90.20MUSDFY2025 · Dec 31, 2025Other Non-cash Items
100.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-127.30MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-79.40MUSDFY2025 · Dec 31, 2025Capital Expenditures
-224.50MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-52.40MUSDFY2025 · Dec 31, 2025Net Acquisitions
-1.39BUSDFY2025 · Dec 31, 2025Purchase of Investments
-300.90MUSDFY2025 · Dec 31, 2025Other Investing Activity
-4.70MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.92BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.49BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.46BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-487.00MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-190.30MUSDFY2025 · Dec 31, 2025Other Financing Charges
-65.50MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
286.30MUSDFY2025 · Dec 31, 2025Shares Outstanding
190.56MSharesUpdated Aug 29, 2026Float Shares
190.12MSharesUpdated Aug 29, 2026Shares Short
8.80MSharesUpdated Aug 29, 2026Short Ratio
3.34daysvs all stocks
Short % of Shares Outstanding
6.08%vs all stocks
% Held by Insiders
0.16%vs all stocks
% Held by Institutions
111.39%vs all stocks
Total Cash (MRQ)
464.50MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.44USDUpdated Aug 29, 2026Total Debt (MRQ)
7.60BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6018xCurrent Ratio (MRQ)
1.69xBook Value per Share (MRQ)
66.23USDUpdated Aug 29, 2026Total Assets
23.09BUSDvs all stocks (USD)
Total Current Assets
5.12BUSDFY2025 · Dec 31, 2025Total Liabilities
10.39BUSDFY2025 · Dec 31, 2025Total Non-current Assets
17.97BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
7.80BUSDFY2025 · Dec 31, 2025Total Current Liabilities
2.58BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
591.90MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.70BUSDFY2025 · Dec 31, 2025Inventory
2.29BUSDFY2025 · Dec 31, 2025Accounts Payable
303.00MUSDFY2025 · Dec 31, 2025Short-term Debt
587.10MUSDFY2025 · Dec 31, 2025Other Current Liabilities
382.00MUSDFY2025 · Dec 31, 2025Long-term Debt
6.93BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
626.10MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.20MUSDFY2025 · Dec 31, 2025Retained Earnings
11.61BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
12.71BUSDvs all stocks (USD)
Treasury Stock
8.89BUSDFY2025 · Dec 31, 202552-Week Low
79.12USDUpdated Aug 29, 202652-Week High
106.88USDUpdated Aug 29, 202652-Week Change
-4.89%vs all stocks
Beta
0.4620xvs all stocks
50-Day MA
93.62USDUpdated Aug 29, 2026200-Day MA
91.06USDUpdated Aug 29, 2026Avg 10-Day Volume
1.25MSharesUpdated Aug 29, 2026Avg 30-Day Volume
2.15MSharesUpdated Aug 29, 2026Diluted EPS (TTM)
4.12USDUpdated Aug 29, 2026Other Income / Expense
-232.60MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Depreciation Intensity
Most of its equipment is already written off, and depreciation is larger against its cash flow than its industry's.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.46: grey zoneSignificant
Altman Z-Score: 2.46
High earnings qualityNotable
Earnings Quality Score: 1.56
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $19.25B, above the global median of $1.18BNotable
Market cap (USD): 19,247,340,196Global Median: 1,179,398,897.704
Revenue is $8.51B, above the global median of $534.05MNotable
Revenue (USD): 8,508,800,000Global Median: 534,052,387.958
Levered free cash flow is $1.09B, above the global median of $19.23MNotable
Levered free cash flow (USD): 1,090,899,968Global Median: 19,234,564.734
Companies that share the same coordination system — how they create, deliver, or capture value.
Viatris Inc.
Tier 1ProductionApproval-Gated PipelineRule
Torrent Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sonova Holding AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sichuan Biokin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
United Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Steris plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jazz Pharmaceuticals plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sino Biopharmaceutical Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Neurocrine Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ipsen S.A.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shutterstock Inc.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthDepreciation Intensity
Telefonica Brasil S.A.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthDepreciation Intensity
Cars.com Inc.
2 interpretationsMulti-Year Revenue, Profit, And Income GrowthDepreciation Intensity